Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Fish and Richardson
Chubb
Johnson and Johnson
Queensland Health
Cantor Fitzgerald
Farmers Insurance
Deloitte
Harvard Business School

Generated: April 20, 2018

DrugPatentWatch Database Preview

LOXITANE Drug Profile

« Back to Dashboard

Which patents cover Loxitane, and what generic alternatives are available?

Loxitane is a drug marketed by Actavis Labs Ut Inc and is included in three NDAs.

The generic ingredient in LOXITANE is loxapine hydrochloride. There are eight drug master file entries for this compound. Additional details are available on the loxapine hydrochloride profile page.
Drug patent expirations by year for LOXITANE
Synonyms for LOXITANE
13-CHLORO-10-(4-METHYLPIPERAZIN-1-YL)-2-OXA-9-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,9,12,14-HEPTAENE; BUTANEDIOIC ACID
1977-10-2 (Parent)
2-Chloro-11-(4-methyl-1- piperazinyl)-dibenz[b,f][1,4]- oxazepine succinate
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine succinate (1:1)
2-Chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine, Succinate
2-chloro-11-(4-methyl-1-piperazinyl)dibenzo[b,f][1,4]oxazepine succinate
27833-64-3
833L643
AC1L2G38
AC1Q5VQU
AKOS015994711
AOB5330
AZ-004
AZ-104
BIL2251
Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)
Butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f][1,4]oxazepine (1:1)
butanedioic acid; 8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
butanedioic acid;8-chloro-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine
C-54162
C22H24ClN3O5
CAS-27833-64-3
CCG-39497
CCRIS 1917
CHEBI:6549
CHEMBL1201155
CL 71563
CL-71563
Cloxazepin
CPD000058470
CS-4285
CTK4G0318
D00794
Daxolin
DSSTox_CID_25227
DSSTox_GSID_45227
DSSTox_RID_80764
DTXSID3045227
EINECS 248-682-0
EU-0100720
FT-0653022
HMS1568K06
HMS1922L14
HMS2051E05
HMS2093N20
HMS2095K06
HMS2232N05
HMS3262O21
HMS3374F02
HMS3393E05
HMS3652O10
HY-17390A
KS-1083
Lederle
Lopac-L-106
Loxapac
Loxapine (succinate)
Loxapine succinate
Loxapine succinate (USP)
Loxapine succinate [USAN:USP]
Loxapine succinate [USAN]
Loxapine succinate salt
Loxapine succinate salt, solid
Loxapine succinate, United States Pharmacopeia (USP) Reference Standard
Loxapine, Succinate
Loxapine,succinate
Loxapinesuccinatesalt
Loxipine Succinate
Loxitane (TN)
LP00720
LS-147408
MFCD00069298
MLS000069383
MLS000758291
MLS001146961
MLS001401432
MLS002222201
MolPort-003-666-776
NC00011
NCGC00016160-01
NCGC00016160-02
NCGC00016160-03
NCGC00016160-04
NCGC00016160-05
NCGC00021145-11
NCGC00094068-01
NCGC00094068-02
NCGC00094068-03
NCGC00261405-01
NSC-759578
NSC759578
O287
Opera_ID_1518
Pharmakon1600-02300242
PL001478
Prestwick_304
REGID_for_CID_71399
s4086
SAM001247061
SCHEMBL41643
SMR000058470
SPECTRUM2300242
Staccato-loxapine
Succinic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz(b,f)(1,4)oxazepine (1:1)
Succinic acid, compound with 2-chloro-11-(4-methylpiperazin-1-yl)dibenz(b,f)(1,4)oxazepine (1:1)
Tox21_110311
Tox21_110311_1
Tox21_500720
UNII-X59SG0MRYU
VA11204
VU0239541-8
W-107092
X59SG0MRYU
ZX-AFC001324

US Patents and Regulatory Information for LOXITANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate TABLET;ORAL 017525-008 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 DISCN Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE C loxapine hydrochloride CONCENTRATE;ORAL 017658-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for LOXITANE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-004 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Actavis Labs Ut Inc LOXITANE loxapine succinate CAPSULE;ORAL 017525-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Moodys
Harvard Business School
Citi
Fish and Richardson
Chinese Patent Office
Julphar
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.